CTORHealthcare · Drug Manufacturers - Specialty & Generic

CTOR Stock Forecast: Citius Oncology, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$0.74

The 1 Wall Street analysts covering Citius Oncology, Inc. hold a median 12-month price target of $4 — +437.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$79.3M

Ticker Nerd rank

15 / 100

Median analyst target

$4.00

Analysts covering

Revenue$1.7M

Operating income−$28.6M

Net income−$26.6M

Free cash flow−$4.4M

Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown

Ticker Nerd rank

CTOR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Citius Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Quality

Value

Revisions

Volatility

Growth

Issuance

Momentum

Size (79): Smaller than most of the companies we track.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTOR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTOR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +437.8% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
23 Sept 2025	Maxim Group	Upgrade	Buy	$6.00
23 May 2025	Maxim Group	Downgrade	Hold	—
27 Nov 2024	Maxim Group	Initiates	Buy	—
13 Aug 2024	EF Hutton	Maintains	Buy	—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTOR appears on the weeks it earns a place.

Estimates

CTOR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Citius Oncology, Inc. (CTOR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −2.2×
Price / sales: 11.2×
Price / book: 2.0×
EV / EBITDA: −3.1×

Growth & margins

Revenue growth (YoY): −57.7%
Earnings growth (YoY): —
Gross margin: 80.3%
Operating margin: −595.6%
Net margin: 0.0%

Returns & dividend

Return on equity: −126.6%
Return on assets: −29.1%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Citius Oncology, Inc. (CTOR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Citius Oncology, Inc. has a market value of $79.3M and an enterprise value of $73.0M.
Revenue in the twelve months to 31 Mar 2026: $5.6M. The latest quarter shrank 57.7% year on year.
Net income over the same four quarters: −$42.5M, a −757.6% net margin.
Free cash flow in the twelve months to 31 Mar 2026: −$27.4M.
Shares outstanding: 93.0M.
Trailing P/E: −2.2×; forward P/E: 7.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Citius Oncology, Inc. employs 0 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

CTOR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic

Company	Market cap	TKN rank
CTORCitius Oncology, Inc.	$79.3M	15
ZYBTZhengye Biotechnology Holding Ltd.	$60.6M	47
TLPHTalphera, Inc.	$59.6M	42
INCRInterCure Ltd.	$51.0M	12
SCYXSCYNEXIS, Inc.	$50.6M	43
BGMBGM Group Ltd.	$110.3M	33
IXHLIncannex Healthcare, Inc.	$42.7M	23

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Citius Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTOR news & analysis

Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 14 Aug 2026positive

Citius Oncology reported fiscal third quarter 2026 financial results ended June 30, 2026, and provided a business update. The company generated $7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR launch progresses, with strong institutional demand driving growth in total vials ordered and the number of institutions ordering LYMPHIR, which has been ordered by 44 institutions since launch.

Why it matters — This update signals early commercial traction for LYMPHIR, reflected in growing order volume and institutional adoption, which is a key metric for CTOR watchers tracking the launch's progress.

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

PRNewsWire · 14 Aug 2026positive

Citius Pharmaceuticals reported fiscal third quarter 2026 financial results and provided a business update, including progress at its majority-owned subsidiary Citius Oncology (CTOR). The company reported $7.1 million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR, held $17 million in cash and cash equivalents as of June 30, 2026, and expanded its LYMPHIR commercial and medical affairs organizations nationwide.

Why it matters — The results signal commercial traction for LYMPHIR and ongoing development of CTOR, Citius Pharma's majority-owned oncology subsidiary that CTOR watchers follow.

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

PRNewsWire · 12 Aug 2026neutral

Citius Oncology announced that its Board of Directors voted to appoint Jonathan Peri, Ph.D., as an independent director, as reported via PRNewswire on Aug. 12, 2026.

Why it matters — A CTOR watcher would care because adding an independent director expands board composition and could bring additional governance oversight to the oncology-focused biopharmaceutical company.

Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment

PRNewsWire · 5 Aug 2026positive

Citius Oncology reported that institutional accounts ordering LYMPHIR rose 78% quarter over quarter, with near-universal payer coverage expanding market access for its cutaneous T-cell lymphoma treatment. The company also noted continued formulary progress at priority U.S. treatment centers supporting LYMPHIR's commercial launch.

Why it matters — A CTOR watcher would care because these indicators suggest growing adoption and improving market access for the company's key cancer treatment, LYMPHIR.

FAQ

Frequently asked questions about CTOR stock

What is the CTOR stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Citius Oncology, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTOR stock a buy right now?

Of the 1 analysts covering Citius Oncology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Citius Oncology, Inc. 15 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTOR?

As at 22 Aug 2026, Citius Oncology, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (79 of 100).

Will CTOR stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +437.8% from the last close, and Ticker Nerd's factor model ranks Citius Oncology, Inc. 15 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTOR stock forecast for 2030?

No analyst covering Citius Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

What does Citius Oncology, Inc. do?

Citius Oncology Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for cancer treatment.

What is the latest news on CTOR?

The most recent item we track (PRNewsWire, 14 Aug 2026): "Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update". Citius Oncology reported fiscal third quarter 2026 financial results ended June 30, 2026, and provided a business update. The company generated $7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR launch progresses, with strong institutional demand driving growth in total vials ordered and the number of institutions ordering LYMPHIR, which has been ordered by 44 institutions since launch.

Company

About Citius Oncology, Inc.

Citius Oncology Inc. operates as a clinical-stage biopharmaceutical company specializing in the development of novel therapeutics for cancer treatment. The primary function of Citius Oncology is to research and develop innovative therapies that aim to enhance the efficacy and safety profiles of current cancer treatments. The company focuses on leveraging new technology platforms and scientific advancements to address unmet medical needs in various types of cancer, impacting both the oncology and pharmaceutical sectors. Citius Oncology's significance in the market revolves around its commitment to advancing cancer therapeutics, which is a critical area due to the disease's widespread impact globally. As a clinical-stage entity, the company plays a crucial role in the pipeline of medical innovation, contributing to potential future options for cancer care. Citius Oncology partners with research institutions and other biopharmaceutical enterprises to push the boundaries of standard oncology treatments. This makes it an influential player in the biotechnology and healthcare sectors, aligning with a broader industry goal to improve patient outcomes in oncology.

CEO Mr. Leonard L. Mazur · United States · https://citiusonc.com/overview/default.aspx